Antisense modulation of PTPN2 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorIan Popoff
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of PTPN2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN2. Methods of using these compounds for modulation of PTPN2 expression and for treatment of diseases associated with expression of PTPN2 are provided.
Claims26
A compound 8 to 50 nucleobases in length targeted to nucleobases 6 through 55 of a 5′ untranslated region, nucleobases 57 through 76 of a start codon region, nucleobases 87 through 118, nucleobases 146 through 246, nucleobases 256 through 275, nucleobases 278 through 302, nucleobases 304 through 370, nucleobases 373 through 460, nucleobases 478 through 516, nucleobases 518 through 607, nucleobases 642 through 661, nucleobases 691 through 762, nucleobases 777 through 796, nucleobases 845 through 864, nucleobases 943 through 962, nucleobases 1158 through 1177, nucleobases 1204 through 1223, or nucleobases 1249 through 1268 of a coding region, or nucleobases 1314 through 1333, nucleobases 1340 through 1359, nucleobases 1368 through 1387, nucleobases 1453 through 1472, nucleobases 1744 through 1763, or nucleobases 2026 through 2045 of a 3′ untranslated region of human PTPN2 (SEQ ID NO:
- 3), wherein said compound specifically hybridizes with one of said regions and inhibits the expression of human PTPN2 (SEQ ID NO:
- 3).
A compound up to 50 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO:
- 14, 17, 18, 19, 22, 24, 25, 26, 27, 28, 31, 32, 34, 36, 37, 38, 39, 41, 42, 43, 44, 45, 47, 49, 50, 52, 55, 56, 59, 60, 64, 72, 78, 81, 84 or 86 which inhibits the expression of human PTPN2.
Dependencies are inferred from the claim text.